Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

 KYMR – Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.
KYMR
$44.10
Name : Kymera Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,153,043,968.00
EPSttm : -3.49
finviz dynamic chart for KYMR
Kymera Therapeutics, Inc.
$44.10
3.55%
$1.51

Float Short %

13.17

Margin Of Safety %

Put/Call OI Ratio

0.27

EPS Next Q Diff

0.05

EPS Last/This Y

-0.42

EPS This/Next Y

-0.8

Price

44.09

Target Price

60.37

Analyst Recom

1

Performance Q

46.17

Relative Volume

0.58

Beta

2.19

Ticker: KYMR




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25KYMR45.720.25999.993289
2025-07-28KYMR44.180.260.113324
2025-07-29KYMR43.720.260.143334
2025-07-30KYMR44.080.262.503342
2025-07-31KYMR43.80.262.503346
2025-08-01KYMR42.940.260.503353
2025-08-04KYMR43.660.260.503353
2025-08-05KYMR42.940.270.003362
2025-08-06KYMR41.310.262.503373
2025-08-07KYMR40.790.262.503373
2025-08-08KYMR40.620.270.803379
2025-08-11KYMR37.920.283.513460
2025-08-12KYMR39.860.260.273408
2025-08-13KYMR40.780.260.233436
2025-08-14KYMR41.580.260.833440
2025-08-15KYMR42.660.260.243440
2025-08-18KYMR43.610.280.381527
2025-08-19KYMR42.60.280.001593
2025-08-20KYMR42.350.280.021596
2025-08-21KYMR42.580.280.061617
2025-08-22KYMR44.090.272.001648
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25KYMR45.79-37.4-37.3-3.49
2025-07-28KYMR44.27-37.4-27.3-3.49
2025-07-29KYMR43.70-37.4-34.1-3.49
2025-07-30KYMR44.07-37.5-40.4-3.49
2025-07-31KYMR43.75-37.5-35.4-3.49
2025-08-01KYMR42.96-37.5-31.8-3.49
2025-08-04KYMR43.66-37.5-43.0-3.49
2025-08-05KYMR42.97-37.5-32.7-3.49
2025-08-06KYMR41.30-37.5-25.4-3.49
2025-08-07KYMR40.85-37.5-33.9-3.49
2025-08-08KYMR40.62-37.5-35.8-3.49
2025-08-11KYMR37.67-37.5-14.4-3.49
2025-08-12KYMR39.88-37.5-85.9-3.49
2025-08-13KYMR40.73-37.5-10.7-3.49
2025-08-14KYMR41.56-0.736.9-3.49
2025-08-15KYMR42.62-37.535.4-3.41
2025-08-18KYMR43.64-37.536.1-3.41
2025-08-19KYMR42.570.449.8-3.41
2025-08-20KYMR42.340.444.5-3.41
2025-08-21KYMR42.580.441.4-3.41
2025-08-22KYMR44.090.432.7-3.40
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25KYMR7.474.7813.22
2025-07-28KYMR7.473.6912.99
2025-07-29KYMR8.183.6912.99
2025-07-30KYMR8.183.6912.99
2025-07-31KYMR8.183.6912.99
2025-08-01KYMR8.183.6912.99
2025-08-04KYMR8.184.2812.99
2025-08-05KYMR8.184.2812.99
2025-08-06KYMR8.184.2812.99
2025-08-07KYMR8.184.2812.99
2025-08-08KYMR8.184.2812.99
2025-08-11KYMR8.184.2812.99
2025-08-12KYMR8.184.2813.30
2025-08-13KYMR8.184.2813.30
2025-08-14KYMR7.984.2813.06
2025-08-15KYMR7.984.2813.06
2025-08-18KYMR7.986.9113.10
2025-08-19KYMR7.856.9113.17
2025-08-20KYMR7.636.9113.17
2025-08-21KYMR7.636.9113.17
2025-08-22KYMR7.636.9113.17
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.95

Avg. EPS Est. Current Quarter

-0.82

Avg. EPS Est. Next Quarter

-0.9

Insider Transactions

7.63

Institutional Transactions

6.91

Beta

2.19

Average Sales Estimate Current Quarter

20

Average Sales Estimate Next Quarter

18

Fair Value

Quality Score

26

Growth Score

26

Sentiment Score

85

Actual DrawDown %

52

Max Drawdown 5-Year %

-87.5

Target Price

60.37

P/E

Forward P/E

PEG

P/S

70.52

P/B

3.2

P/Free Cash Flow

EPS

-3.48

Average EPS Est. Cur. Y​

-3.4

EPS Next Y. (Est.)

-4.2

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-616.03

Relative Volume

0.58

Return on Equity vs Sector %

-53

Return on Equity vs Industry %

-40.1

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.09

EBIT Estimation

32.7
Kymera Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 218
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
stock quote shares  KYMR – Kymera Therapeutics, Inc. Stock Price stock today
news today  KYMR – Kymera Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch  KYMR – Kymera Therapeutics, Inc. yahoo finance google finance
stock history  KYMR – Kymera Therapeutics, Inc. invest stock market
stock prices KYMR premarket after hours
ticker KYMR fair value insiders trading